Accumulation of Axonal Injury and Neurodegenerative Changes Associated With Repetitive Subconcussive Head Acceleration Exposures in a Biofidelic Preclinical Model

Rachel Cutlan, Jack Seifert, Alok Shah, Rachel Chiariello, Matthew D. Budde, Christopher M. Olsen, Michael A. McCrea, Brian D. Stemper

Introduction

• Contact sport athletes experience subconcussive head impacts during routine practice
• This subconcussive Head Impact Exposure (sHIE) can lead to a decreased concussion threshold and an increased concussion risk
• Blood biomarkers correlated with this sHIE would help identify at risk athletes ahead of concussions

Goal

This analysis was conducted to determine which blood serum biomarkers correlated with different head impact exposures.

Methods

• Rats experienced head accelerations scaled from our study on contact sport athletes
• Blood was drawn at different time points to track various biomarkers

High Exposure (HE): 30 head accelerations/day, 5 days a week, for 4 weeks
Moderate Exposure (ME): 8 head accelerations/day, 5 days a week, for 4 weeks
Single Impact (SI): 1 high magnitude head acceleration
Sham: No head accelerations

Blood Serum Biomarkers:

• Neurofilament light (NFL): axonal damage
• Glial Fibrillary Acidic Protein (GFAP): astrocyte damage
• Total Tau (t-tau): neuron death
• Neuron Specific Enolase (NSE): neuron injury

Discussion

• This analysis showed a dose dependent response between sHIE and certain blood serum biomarkers
• HE rats saw significantly elevated NFL levels which may indicate significant axonal damage while ME rats did not.
• This finding supports the idea that limiting excessive sHIE may be protective.
• The peaks of T-tau at the terminal measurement may be indicative of a chronic injury.
• Future areas of study could include further exploring this phenomenon.

Acknowledgements

This project was funded through the Advancing a Healthier Wisconsin Endowment at the Medical College of Wisconsin, Daniel M. Soref Charitable Trust; Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development project number 5I01RX002931-03; and Veterans Affairs Medical Research.